{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hives&page=2",
    "query": {
      "condition": "Hives",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hives&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-11T01:43:23.243Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03485911",
      "title": "Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hereditary Angioedema",
        "HAE"
      ],
      "interventions": [
        {
          "name": "BCX7353 capsules",
          "type": "DRUG"
        },
        {
          "name": "Placebo oral capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BioCryst Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 121,
      "start_date": "2018-02-06",
      "completion_date": "2022-04-06",
      "has_results": true,
      "last_update_posted_date": "2023-06-26",
      "last_synced_at": "2026-06-11T01:43:23.243Z",
      "location_count": 27,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 24 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03485911"
    },
    {
      "nct_id": "NCT05047185",
      "title": "Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hereditary Angioedema",
        "Hereditary Angioedema Type I",
        "Hereditary Angioedema Type II",
        "Hereditary Angioedema Types I and II",
        "Hereditary Angioedema Attack",
        "Hereditary Angioedema With C1 Esterase Inhibitor Deficiency",
        "Hereditary Angioedema - Type 1",
        "Hereditary Angioedema - Type 2",
        "C1 Esterase Inhibitor Deficiency",
        "C1 Inhibitor Deficiency"
      ],
      "interventions": [
        {
          "name": "Deucrictibant low dose",
          "type": "DRUG"
        },
        {
          "name": "Deucrictibant high dose",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pharvaris Netherlands B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 34,
      "start_date": "2022-04-19",
      "completion_date": "2025-06-30",
      "has_results": false,
      "last_update_posted_date": "2025-07-30",
      "last_synced_at": "2026-06-11T01:43:23.243Z",
      "location_count": 3,
      "location_summary": "Birmingham, Alabama • Paradise Valley, Arizona • St Louis, Missouri",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Paradise Valley",
          "state": "Arizona"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05047185"
    },
    {
      "nct_id": "NCT05121376",
      "title": "A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hereditary Angioedema",
        "HAE"
      ],
      "interventions": [
        {
          "name": "Dose 1 of BMN 331",
          "type": "GENETIC"
        },
        {
          "name": "Dose 2 of BMN 331",
          "type": "GENETIC"
        },
        {
          "name": "Dose 3 of BMN 331",
          "type": "GENETIC"
        },
        {
          "name": "Dose 4 of BMN 331",
          "type": "GENETIC"
        },
        {
          "name": "Dose 5 of BMN 331",
          "type": "GENETIC"
        },
        {
          "name": "Dose 6 of BMN 331",
          "type": "GENETIC"
        },
        {
          "name": "Dose 7 of BMN 331",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "BioMarin Pharmaceutical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2022-02-15",
      "completion_date": "2028-11",
      "has_results": false,
      "last_update_posted_date": "2024-05-16",
      "last_synced_at": "2026-06-11T01:43:23.243Z",
      "location_count": 13,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 10 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05121376"
    },
    {
      "nct_id": "NCT05677451",
      "title": "24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Spontaneous Urticaria"
      ],
      "interventions": [
        {
          "name": "LOU064 (blinded)",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 100,
      "start_date": "2023-07-11",
      "completion_date": "2032-03-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-05",
      "last_synced_at": "2026-06-11T01:43:23.243Z",
      "location_count": 12,
      "location_summary": "Bakersfield, California • San Diego, California • Miami, Florida + 9 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Boise",
          "state": "Idaho"
        },
        {
          "city": "Glenview",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05677451"
    },
    {
      "nct_id": "NCT05030311",
      "title": "A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Spontaneous Urticaria"
      ],
      "interventions": [
        {
          "name": "LOU064 25 mg (b.i.d)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "LOU064 25 mg (b.i.d) as a tablet.",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 470,
      "start_date": "2021-11-30",
      "completion_date": "2024-01-19",
      "has_results": true,
      "last_update_posted_date": "2025-04-08",
      "last_synced_at": "2026-06-11T01:43:23.243Z",
      "location_count": 26,
      "location_summary": "Birmingham, Alabama • North Little Rock, Arkansas • Bakersfield, California + 23 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "North Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Lancaster",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05030311"
    },
    {
      "nct_id": "NCT06555328",
      "title": "Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Urticaria, Idiopathic",
        "Hidradenitis",
        "Hidradenitis Suppurativa"
      ],
      "interventions": [
        {
          "name": "CSU lower dose treatment",
          "type": "DRUG"
        },
        {
          "name": "CSU high dose treatment",
          "type": "DRUG"
        },
        {
          "name": "CSU non responders IgE - high dose treatment",
          "type": "DRUG"
        },
        {
          "name": "HS low dose treatment",
          "type": "DRUG"
        },
        {
          "name": "HS medium dose treatment",
          "type": "DRUG"
        },
        {
          "name": "HS high dose treatment",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "InflaRx GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 73,
      "start_date": "2025-01-02",
      "completion_date": "2026-01-22",
      "has_results": false,
      "last_update_posted_date": "2026-02-03",
      "last_synced_at": "2026-06-11T01:43:23.243Z",
      "location_count": 9,
      "location_summary": "Fountain Valley, California • North Miami Beach, Florida • Tampa, Florida + 6 more",
      "locations": [
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "North Miami Beach",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Murray",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06555328"
    },
    {
      "nct_id": "NCT00628108",
      "title": "Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Allergic Rhinitis",
        "Chronic Urticaria"
      ],
      "interventions": [
        {
          "name": "Levocetirizine 1.25 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "UCB Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "11 Months",
        "sex": "ALL",
        "summary": "6 Months to 11 Months"
      },
      "enrollment_count": 69,
      "start_date": "2008-03",
      "completion_date": "2008-09",
      "has_results": true,
      "last_update_posted_date": "2015-03-06",
      "last_synced_at": "2026-06-11T01:43:23.243Z",
      "location_count": 26,
      "location_summary": "Birmingham, Alabama • Hot Springs, Arkansas • Jonesboro, Arkansas + 23 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00628108"
    },
    {
      "nct_id": "NCT04976192",
      "title": "Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Urticaria"
      ],
      "interventions": [
        {
          "name": "TEV-45779",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "XOLAIR® Injection",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Teva Pharmaceuticals USA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 608,
      "start_date": "2021-08-30",
      "completion_date": "2024-04-05",
      "has_results": true,
      "last_update_posted_date": "2025-10-07",
      "last_synced_at": "2026-06-11T01:43:23.243Z",
      "location_count": 9,
      "location_summary": "Bakersfield, California • Clearwater, Florida • Coral Gables, Florida + 6 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Kissimmee",
          "state": "Florida"
        },
        {
          "city": "Maitland",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04976192"
    },
    {
      "nct_id": "NCT07298447",
      "title": "Donidalorsen Treatment in Children With Hereditary Angioedema",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hereditary Angioedema (HAE)"
      ],
      "interventions": [
        {
          "name": "Donidalorsen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ionis Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "2 Years to 11 Years"
      },
      "enrollment_count": 20,
      "start_date": "2026-04-21",
      "completion_date": "2029-06",
      "has_results": false,
      "last_update_posted_date": "2026-05-28",
      "last_synced_at": "2026-06-11T01:43:23.243Z",
      "location_count": 5,
      "location_summary": "Santa Monica, California • Miami, Florida • St Louis, Missouri + 2 more",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07298447"
    },
    {
      "nct_id": "NCT02935699",
      "title": "Clinical Trial Comparing JDP-205 to Diphenhydramine Injection for the Treatment of Acute Urticaria",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Urticaria"
      ],
      "interventions": [
        {
          "name": "Test Drug (JDP-205)",
          "type": "DRUG"
        },
        {
          "name": "Active Control (Diphenhydramine)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "JDP Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 262,
      "start_date": "2017-03-01",
      "completion_date": "2018-04-30",
      "has_results": true,
      "last_update_posted_date": "2019-11-27",
      "last_synced_at": "2026-06-11T01:43:23.243Z",
      "location_count": 3,
      "location_summary": "Cincinnati, Ohio • Philadelphia, Pennsylvania • Dallas, Texas",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02935699"
    }
  ]
}